These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34499691)

  • 1. COVID-19 and financial market response in China: Micro evidence and possible mechanisms.
    Wang Z; Zhang Z; Zhang Q; Gao J; Lin W
    PLoS One; 2021; 16(9):e0256879. PubMed ID: 34499691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does working capital management improve financial performance in China's agri-food sector during COVID-19? A comparison with the 2008 financial crisis.
    Liu L; Zhou X; Xu J
    PLoS One; 2024; 19(4):e0300217. PubMed ID: 38568957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial performance of China's listed firms in presence of coronavirus: Evidence from corporate culture and corporate social responsibility.
    Zheng F; Zhao Z; Sun Y; Khan YA
    Curr Psychol; 2023; 42(11):8897-8918. PubMed ID: 34400856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research on Monetary Policy Implementation and Industrial Structure Transformation Under COVID-19-Evidence From Eight Economic Zones in Mainland China.
    Zhou B; Wang S; Gao H; Wang H
    Front Public Health; 2022; 10():865699. PubMed ID: 35669741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of COVID-19 and economic policy uncertainty on China's stock market returns: evidence from quantile-on-quantile and causality-in-quantiles approaches.
    Ullah A; Zhao X; Amin A; Syed AA; Riaz A
    Environ Sci Pollut Res Int; 2023 Jan; 30(5):12596-12607. PubMed ID: 36109486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Firms' COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China.
    He Z; Suardi S; Wang K; Zhao Y
    Econ Model; 2022 Nov; 116():105999. PubMed ID: 36032988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capital structure and financial performance of China's energy industry: What can we infer from COVID-19?
    Samour A; AlGhazali A; Gadoiu M; Banuta M
    PLoS One; 2024; 19(6):e0300936. PubMed ID: 38843206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can capital markets identify heterogeneous environmental investment strategies of firms? Evidence from China.
    Cheng H; Feng Y
    Environ Sci Pollut Res Int; 2023 Apr; 30(20):58253-58275. PubMed ID: 36977868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncertainty in banking and debt financing of firms in Vietnam.
    Huynh J; Phan TMH
    PLoS One; 2024; 19(7):e0305724. PubMed ID: 39008440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial risk of the biotech industry versus the pharmaceutical industry.
    Golec J; Vernon JA
    Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does CSR performance improve corporate immunity to the COVID-19 pandemic? Evidence from China's stock market.
    Tian J; Wang X; Wei Y
    Front Public Health; 2022; 10():956521. PubMed ID: 36052006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evidence on the impact of the COVID-19 outbreak and vaccine discovery on the global transportation industry.
    Maneenop S; Kotcharin S
    Transp Res Interdiscip Perspect; 2023 Jan; 17():100741. PubMed ID: 36618962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying dynamic risk spillovers between crude oil and downstream industries: China's futures market perspective.
    Hao Y; Liu H; Wang X; Liu J
    Environ Sci Pollut Res Int; 2024 Mar; 31(14):21089-21106. PubMed ID: 38379046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid deep learning models with multi-classification investor sentiment to forecast the prices of China's leading stocks.
    Niu H; Pan Q; Xu K
    PLoS One; 2023; 18(11):e0294460. PubMed ID: 38011183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 impact on firm investment-Evidence from Chinese publicly listed firms.
    Jiang J; Hou J; Wang C; Liu H
    J Asian Econ; 2021 Aug; 75():101320. PubMed ID: 36567767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of economic policy uncertainty on firms' investment in innovation: Evidence from Chinese listed firms.
    Kun W; Hu X; Liu F
    PLoS One; 2022; 17(11):e0272983. PubMed ID: 36378624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach.
    Hu Y; Chen S; Qiu F; Chen P; Chen S
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How does capital structure change product-market competitiveness? Evidence from Chinese firms.
    Li L; Wang Z
    PLoS One; 2019; 14(2):e0210618. PubMed ID: 30721237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Air pollution, investor sentiment and stock liquidity.
    Li C; Yan Y; Lu Y; Zeng G; Zhou L; Jin H; Xu Y; Chen Y
    Front Public Health; 2022; 10():989457. PubMed ID: 36276384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the COVID-19 Pandemic on China's Stock Market Volatility, During and After the Outbreak: Evidence From an ARDL Approach.
    Jin C
    Front Public Health; 2022; 10():810102. PubMed ID: 35664100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.